In 111 NSCLC patients with acquired T790M mutation treated with osimertinib after progression on 1G/2G EGFR‐TKIs, the T790M ratio assessed by ddPCR has shown a significant correlation with the osimertinib response.32 Here, EGFR is linked to non-small cell lung carcinoma.